Unlock instant, AI-driven research and patent intelligence for your innovation.

Thienopyridinone compounds

A technology of compound and stereochemistry, applied in the direction of drug combination, organic chemistry, organic active ingredients, etc., can solve the problem of reducing the sensitivity of FGFR inhibitors

Active Publication Date: 2021-08-06
JANSSEN PHARMA NV
View PDF17 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, it has been reported that mutations affecting amino acids in FGFRs (e.g., FGFR1, 2, or 3) can result in resistance or reduced sensitivity to FGFR inhibitors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Thienopyridinone compounds
  • Thienopyridinone compounds
  • Thienopyridinone compounds

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0400] Solvates can be important for methods of preparation of substances (e.g., with respect to their purification, storage of substances (e.g., their stability), and ease of handling substances, and are often used as part of the isolation stage or purification stage of chemical syntheses Formed. Those skilled in the art can determine whether a hydrate or other solvate has been formed by the isolation conditions or purification conditions used to prepare a given compound by means of standard and long-established techniques. Examples of such techniques include thermogravimetric Analytical (TGA), differential scanning calorimetry (DSC), X-ray crystallography (such as single crystal X-ray crystallography or X-ray powder diffraction) and solid-state NMR (SS-NMR, also known as magic-angle spinning NMR or MAS -NMR). Such techniques, like NMR, IR, HPLC, and MS, are part of the skilled chemist's standard analytical toolkit. Alternatively, the skilled person can intentionally form solv...

example 1

[0629]

[0630] a) Preparation of intermediate 1

[0631] 7-Hydroxythieno[3,2-b]pyridin-5(4H)-one

[0632]

[0633] Intermediate 1 was synthesized as described in Journal of Chemical Research, Miniprint, 1980, #1 pp. 113-126.

[0634] General procedure A: 1 H NMR (400MHz, DMSO-d 6 ) (Varian) 7.94 (d, J=5.3Hz, 1H), 7.12 (d, J=5.5Hz, 1H), 6.00 (s, 1H).

[0635] b) Preparation of Intermediate 2

[0636] 6-((phenylamino)methylene)thieno[3,2-b]pyridine-5,7(4H,6H)-dione

[0637]

[0638] A stir bar, Intermediate 1 (7-hydroxythieno[3,2-b]pyridin-5(4H)-one) (65.0 g, 389 mmol) and ethylene glycol (600 mL) were added to a 1 L round bottom flask. The resulting mixture was stirred at 135°C and treated with trimethoxymethane (61.9 g, 583 mmol) and aniline (36.2 g, 389 mmol) in one portion. The resulting mixture was stirred at 135°C for 16 hours. The mixture was cooled to 25°C and filtered. The filter cake was washed with ethanol (100 mL). The solid was dried at 50 °C to g...

example 2

[0668]

[0669] a) Preparation of Intermediate 9

[0670] 2-(cis-2,6-dimethylmorpholino)-5-nitropyridin-4-amine

[0671]

[0672] A stir bar, intermediate 7 (2-chloro-5-nitropyridin-4-amine) (1.00g, 5.76mmol), intermediate 8 (cis-2,6-dimethylmorpholine) (800mg , 6.95mmol), N,N-diisopropylethylamine (2.24g, 17.3mmol) and n-butanol (10mL) were added to a 40mL glass bottle, which was stirred at 110°C for 16 hours. The mixture was cooled to room temperature with the formation of a yellow solid. The precipitate was filtered and washed with ethanol (5 mL x 3) to give Intermediate 9 (1.50 g, 90.0% purity, 92.9% yield) as a yellow powder.

[0673] b) Preparation of Intermediate 10

[0674] 6-(cis-2,6-dimethylmorpholino)pyridine-3,4-diamine

[0675]

[0676] A stir bar, intermediate 9 (2-(cis-2,6-dimethylmorpholino)-5-nitropyridin-4-amine) (1.50 g, 5.95 mmol) and methanol (50 mL) were added to 75 mL of hydrogenated glass, then wet palladium on carbon (400 mg, 50% aqueous ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

New thienopyridinone compounds, pharmaceutical compositions comprising said compounds, processes for the preparation of said compounds and the use of said compounds as FGFR (fibroblast growth factor receptor) inhibitors and their use in the treatment of diseases e.g.cancer are provided.

Description

technical field [0001] The present invention relates to novel thienopyridone compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds as FGFR (fibroblast growth factor receptor) inhibitors , and relates to the use of said compound in the treatment of diseases such as cancer. Background technique [0002] The fibroblast growth factor (FGF) signaling pathway has been shown to play a key role in processes ranging from embryogenesis to wound healing, and has also been shown to be strongly associated with several hallmarks of cancer. Genetic alterations in FGFR family members are associated with tumor growth, metastasis, angiogenesis and survival. Multiple FGFR inhibitors are in clinical trials and have shown clinical responses in patients with FGFR aberrations. However, it has been reported that mutations affecting amino acids in a FGFR (eg, FGFR1, 2 or 3) can result in resistance o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D495/04A61K31/4436A61K31/444A61K31/551A61K31/4365A61P35/00
CPCA61P35/00C07D519/00C07D495/04A61K31/5377A61K31/506
Inventor 秦泺恒万昭奎郭海兵刘谦
Owner JANSSEN PHARMA NV